ZoetisZTS

NYSE · USA · Segment 2 of 8 in the Medicine, pharma & life science value chain: Big pharma

Spun out of Pfizer in 2013 to sell animal medicines and vaccines. Simparica handles parasites while Librela and Solensia treat pain, with pets on one side of the business and livestock on the other.

Big pharma: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.

Key metrics

Market cap

$30.2B

Price

$77.17

Today

−0.7%

Return YTD

−38.2%

Return 1Y

−50.0%

P/E

11.5

P/S

3.2

P/B

9.6

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Animal healthPetsDefensive growthPet medicineLivestock & foodDiagnostics

In the value chain

Products & services

Simparica (parasiticide)
Librela / Solensia (pain)
Vaccines

Competitors

Merck Animal Health
Elanco
Boehringer Ingelheim

Risks

Pet spending is cyclical
Generic competition

Supply chain

← Suppliers

Charles River LaboratoriesCRL

Full supply chain for ZTS →

Same segment: Big pharma

Johnson & JohnsonJNJ AbbVieABBV Merck & Co.MRK PfizerPFE Bristol Myers SquibbBMY

Compare ZTS

ZTS vs JNJ ZTS vs ABBV ZTS vs MRK ZTS vs PFE ZTS vs BMY

See where Zoetis sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →